Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 24, 2018

Boston Scientific gets FDA approval for blood device

Courtesy | Boston Scientific Boston Scientific's headquarters are located in Marlborough.

Marlborough medical device giant Boston Scientific has been approved by U.S. regulators to market a device that helps deliver a sustained release of a drug to treat peripheral artery disease.

The U.S. Food and Drug Administration approved the company’s Eluvia Drug-Eluting Vascular Stent System, which uses a drug-polymer combination to provide sustained release of the drug paclitaxel for a year.

FDA approval follows a two-year trial that found the Eluvia stent demonstrated superior results than the company’s Indiana-based competitor Cook Medical, which offers a similar device.

In the trial, patients treated with Boston Scientific’s device experienced a greater 12-month primary patency of 88.5 percent compared to 79.5 percent in patients treated with Cook Medical’s device.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF